Fund moves
3 tracked managers disclosed the same change for Q4 2024. From a 13F filed Jan 17, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 6, 2025 · Filed Jan 7, 2025
The CFO of Viking Therapeutics sold $204K of Viking Therapeutics shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$203,601
Shares × reported transaction price
75 days after results of Oct 23, 2024, 30 days before results of Feb 5, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
Fund moves
3 tracked managers disclosed the same change for Q4 2024. From a 13F filed Jan 17, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Greg Zante (Chief Financial Officer) sold ~$1.95M of Viking Therapeutics
Automatic saleMarianna Mancini (Chief Operating Officer) sold ~$2.1M of Viking Therapeutics
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.